0.324
price up icon7.35%   0.0221
 
loading
Schlusskurs vom Vortag:
$0.3019
Offen:
$0.2974
24-Stunden-Volumen:
2.02M
Relative Volume:
3.46
Marktkapitalisierung:
$9.35M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.77M
KGV:
-0.0212
EPS:
-15.2954
Netto-Cashflow:
$-24.23M
1W Leistung:
+6.79%
1M Leistung:
-62.75%
6M Leistung:
-80.94%
1J Leistung:
-90.61%
1-Tages-Spanne:
Value
$0.2911
$0.33
1-Wochen-Bereich:
Value
$0.28
$0.42
52-Wochen-Spanne:
Value
$0.25
$4.707

Moleculin Biotech Inc Stock (MBRX) Company Profile

Name
Firmenname
Moleculin Biotech Inc
Name
Telefon
713-300-5160
Name
Adresse
5300 MEMORIAL DRIVE, HOUSTON, TX
Name
Mitarbeiter
17
Name
Twitter
@moleculinbio
Name
Nächster Verdiensttermin
2024-12-08
Name
Neueste SEC-Einreichungen
Name
MBRX's Discussions on Twitter

Vergleichen Sie MBRX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
MBRX
Moleculin Biotech Inc
0.324 9.35M 0 -29.77M -24.23M -15.30
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
451.34 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
536.31 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
323.87 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
553.46 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.50 28.51B 3.81B -644.79M -669.77M -6.24

Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-09 Fortgesetzt H.C. Wainwright Buy
2025-02-12 Herabstufung Maxim Group Buy → Hold
2022-07-18 Fortgesetzt Oppenheimer Outperform

Moleculin Biotech Inc Aktie (MBRX) Neueste Nachrichten

pulisher
Jun 18, 2025

Moleculin Biotech (MBRX) Rating Reiterated with $4.00 Price Target | MBRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML - GlobeNewswire

Jun 18, 2025
pulisher
Jun 18, 2025

Moleculin Participates in Virtual Investor “What This Means” Seg - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Moleculin Biotech’s Annamycin Pediatric Study Approved by FDA - TipRanks

Jun 18, 2025
pulisher
Jun 18, 2025

Moleculin Participates in Virtual Investor “What This Means” Segment - GlobeNewswire

Jun 18, 2025
pulisher
Jun 18, 2025

Moleculin Biotech (MBRX) Advances Pediatric Cancer Treatment Study | MBRX Stock News - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Moleculin Receives Critical FDA Support for Children's Leukemia Treatment Development - Stock Titan

Jun 18, 2025
pulisher
Jun 18, 2025

Moleculin Biotech, Inc. Advances Annamycin for Pediatric Cancer Treatment as FDA Approves Inclusion of Younger Patients in Clinical Study - Nasdaq

Jun 18, 2025
pulisher
Jun 18, 2025

FDA agrees to Moleculin’s pediatric study plan for cancer drug - Investing.com

Jun 18, 2025
pulisher
Jun 12, 2025

Moleculin Biotech announces ‘What This Means’ virtual investor segment - Yahoo Finance

Jun 12, 2025
pulisher
Jun 12, 2025

What is HC Wainwright’s Estimate for MBRX Q2 Earnings? - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Moleculin Biotech (MBRX) Reports Positive Results from Annamycin Trial | MBRX Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Moleculin Participates in Virtual Investor “What This Means” Segment | MBRX Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Moleculin Biotech, Inc. Reports Positive Topline Results from Phase 1B/2 Trial of Annamycin for Soft Tissue Sarcoma Lung Metastases - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

Research Analysts Offer Predictions for MBRX Q4 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Moleculin Biotech (NASDAQ:MBRX) Stock Rating Upgraded by HC Wainwright - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

Moleculin Biotech (MBRX) Receives "Buy" Rating and $4.00 Price Target | MBRX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 09, 2025

Moleculin Biotech Reports Positive Annamycin Trial Results - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Moleculin Biotech (MBRX) Receives Buy Rating and $4 Price Target | MBRX Stock News - GuruFocus

Jun 09, 2025
pulisher
Jun 05, 2025

Moleculin Biotech Stock (MBRX) Dives 10% on Clinical Trial Results - The Globe and Mail

Jun 05, 2025
pulisher
Jun 05, 2025

Moleculin Releases On-Demand KOL Webcast to Discuss Data - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Transcript : Moleculin Biotech, Inc.Pre Recorded Shareholder/Analyst Call - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Moleculin Biotech, Inc. Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Moleculin Biotech Hosts Key Opinion Leaders Event - TipRanks

Jun 05, 2025
pulisher
Jun 05, 2025

Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits - Quantisnow

Jun 05, 2025
pulisher
Jun 05, 2025

Moleculin Biotech (MBRX) Presents Final Data from Annamycin Clin - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Leading Oncologists Review Breakthrough Data from Moleculin's Sarcoma Lung Metastases Trial - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

Moleculin announces efficacy results from trial of Annamycin for STS lung mets - Yahoo Finance

Jun 05, 2025
pulisher
Jun 04, 2025

Moleculin Reports Positive Topline Efficacy Results from U.S. Ph - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Moleculin Biotech Shares Slump After Phase 1b/2 Trial of Annamycin Fails to Show Complete Responses - MarketScreener

Jun 04, 2025
pulisher
Jun 04, 2025

Moleculin Biotech (MBRX) Reports Promising Phase 1B/2 Trial Resu - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) | MBRX Stock News - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Moleculin Biotech Reports Promising Efficacy Results for Annamycin in Phase 1B/2 Trial for Soft Tissue Sarcoma Lung Metastases - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) - GlobeNewswire

Jun 04, 2025
pulisher
Jun 04, 2025

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107) - GlobeNewswire Inc.

Jun 04, 2025
pulisher
Jun 04, 2025

Breakthrough: Moleculin's Cancer Drug Achieves 59.4% Clinical Benefit Rate in Late-Stage Trial - Stock Titan

Jun 04, 2025
pulisher
Jun 02, 2025

Roth Capital Partners Manages New Developments for Moleculin Biotech (MBRX) | MBRX Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Roth Capital Partners Manages New Developments for Moleculin Bio - GuruFocus

Jun 02, 2025
pulisher
May 23, 2025

Moleculin receives Nasdaq non-compliance notice By Investing.com - Investing.com South Africa

May 23, 2025
pulisher
May 23, 2025

Moleculin Biotech Faces Nasdaq Non-Compliance Notice - TipRanks

May 23, 2025
pulisher
May 23, 2025

Moleculin receives Nasdaq non-compliance notice - Investing.com

May 23, 2025
pulisher
May 19, 2025

Moleculin signals first 45-patient unblinding for Phase 3 AML trial by end of 2025 as key regulatory milestones achieved - MSN

May 19, 2025
pulisher
May 17, 2025

Q2 EPS Forecast for Moleculin Biotech Increased by Analyst - Defense World

May 17, 2025
pulisher
May 16, 2025

Moleculin Biotech reaches agreement to amend investor warrants - MSN

May 16, 2025
pulisher
May 16, 2025

MBRX stock touches 52-week low at $1.46 amid sharp yearly decline - MSN

May 16, 2025
pulisher
May 16, 2025

Moleculin Announces First European Approval for Phase 3 AML Trial - MSN

May 16, 2025
pulisher
May 15, 2025

Moleculin Biotech’s Earnings Call: Trials and Triumphs - TipRanks

May 15, 2025
pulisher
May 15, 2025

Moleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 15, 2025
pulisher
May 15, 2025

Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

Moleculin Biotech Inc (MBRX) Q1 2025 Earnings Call Highlights: S - GuruFocus

May 15, 2025

Finanzdaten der Moleculin Biotech Inc-Aktie (MBRX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Moleculin Biotech Inc-Aktie (MBRX) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
KLEMP WALTER V
CEO and President
Jun 23 '25
Buy
0.37
675,675
250,000
743,607
$20.87
price up icon 0.99%
$35.78
price down icon 0.78%
$21.44
price up icon 0.99%
$98.77
price down icon 2.03%
$108.80
price up icon 2.21%
biotechnology ONC
$245.50
price up icon 1.42%
Kapitalisierung:     |  Volumen (24h):